Kang Tae Wook, Jung Jae Hung, Kim Dong Wook, Lee Kwang Ho, Chung Hyun Chul
Department of Urology, Wonju College of Medicine, Yonsei University, Wonju, Korea.
Department of Anesthesiology, Wonju College of Medicine, Yonsei University, Wonju, Korea.
SAGE Open Med. 2021 Sep 30;9:20503121211047386. doi: 10.1177/20503121211047386. eCollection 2021.
To evaluate efficacy of 0.4 mg tamsulosin monotherapy in patients with benign prostatic hyperplasia with moderate-to-severe International Prostate Symptom Score.
From May 2015 to May 2017, 102 patients were analyzed, retrospectively. The patients were classified into three groups according to the combination of medication (tamsulosin 0.4 mg vs tamsulosin 0.4 mg + solifenacin 5 mg vs tamsulosin 0.4 mg + mirabegron 50 mg). Baseline characteristics (e.g. age, body weight, height, and underlying medical disease) were collected. International Prostate Symptom Score, prostate specific antigen, prostate volume, peak urinary flow rate (Qmax), voided volume, and post-voided volume before after treatment were evaluated.
We classified and analyzed the patients into three groups depending on the medication. And there were no significant differences between all parameters among the groups. Voided volume at 3 months after treatment in each group was 170.54 ± 125.83, 121.55 ± 46.19, and 274.63 ± 132.30 ( = 0.019). Differences of voiding symptom score and difference of post-voided volume among the groups before after treatment was 5.00 ± 5.42, 1.92 ± 3.92, and 0.11 ± 5.11 and 8.37 ± 34.32, 0.78 ± 14.86, -33.63 ± 28.58 ( = 0.037, = 0.007).
We think tamsulosin monotherapy will be feasible as a first-line therapy for the patients with benign prostatic hyperplasia who has struggled with moderate-to-severe lower urinary tract symptoms.
评估0.4毫克坦索罗辛单药治疗对国际前列腺症状评分中重度的良性前列腺增生患者的疗效。
回顾性分析2015年5月至2017年5月期间的102例患者。根据用药组合将患者分为三组（坦索罗辛0.4毫克组、坦索罗辛0.4毫克+索利那新5毫克组、坦索罗辛0.4毫克+米拉贝隆50毫克组）。收集基线特征（如年龄、体重、身高和基础疾病）。评估治疗前后的国际前列腺症状评分、前列腺特异性抗原、前列腺体积、最大尿流率（Qmax）、排尿量和残余尿量。
我们根据用药情况将患者分为三组并进行分析。各组之间所有参数均无显著差异。每组治疗3个月后的排尿量分别为170.54±125.83、121.55±46.19和274.63±132.30（P=0.019）。治疗前后各组间排尿症状评分差异及残余尿量差异分别为5.00±5.42、1.92±3.92和0.11±5.11，以及8.37±34.32、0.78±14.86、-33.63±28.58（P=0.037，P=0.007）。
我们认为坦索罗辛单药治疗对于有中重度下尿路症状的良性前列腺增生患者作为一线治疗是可行的。
